Drugs / DWJ1248
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04721535 | Jun → Sep 2021 | COVID-19 | Daewoong Pharmaceutical Co. LTD. | Terminated | No outcome recorded |
| Phase 3 | NCT04713176 | Feb 2021 → May 2022 | COVID-19 | Daewoong Pharmaceutical Co. LTD. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DWJ1248 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04713176 ↗ |
| Route | Oral | “1 tablet of DWJ1248 TID(up to 14 days) PO” NCT04713176 ↗ |